GH Research (NASDAQ:GHRS) Shares Up 1.4% – Still a Buy?

Shares of GH Research PLC (NASDAQ:GHRS) were up 1.4% on Monday . The stock traded as high as $9.72 and last traded at $9.40. Approximately 10,151 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 79,479 shares. The stock had previously closed at $9.27.

Analyst Ratings Changes

Several equities research analysts have issued reports on GHRS shares. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of GH Research in a research report on Wednesday, November 20th. JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a report on Wednesday, September 4th. Finally, Canaccord Genuity Group cut their target price on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th.

GH Research Price Performance

The company has a 50 day simple moving average of $7.91 and a 200-day simple moving average of $10.29. The firm has a market cap of $473.99 million, a PE ratio of -11.71 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. On average, sell-side analysts predict that GH Research PLC will post -0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. lifted its position in GH Research PLC (NASDAQ:GHRS) by 1.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).